NCT01212744
Phenylketonuria
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The purpose of this study is to evaluate the effect of daily administration of rAvPAL-PEG on the reduction of blood Phe concentrations in subjects with PKU.
All
16 Years to 70 Years
No
rAvPAL-PEG
Phase 2
Interventional
16
2011-03
2019-02-26
Aurora, Colorado, United States
Gainesville, Florida, United States
Louisville, Kentucky, United States
Columbia, Missouri, United States
Saint Louis, Missouri, United States
Albany, New York, United States
Columbus, Ohio, United States
Pittsburgh, Pennsylvania, United States
Madison, Wisconsin, United States
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields